What did Aquestive Therapeutics (AQST) disclose about COO Cassie Jung’s latest share transaction?

Aquestive Therapeutics reported that 72,734 shares of common stock were withheld at $4.18 per share to cover COO Cassie Jung’s tax obligations from vested Performance Stock Units, leaving her with 202,246 directly held shares plus 2,000 shares held by her spouse.

What triggered the tax-withholding share disposition for AQST COO Cassie Jung?

The disposition was triggered by the vesting of Performance Stock Units (PSUs) previously granted to COO Cassie Jung . To cover her resulting tax withholding obligation, the issuer retained 72,734 shares of common stock rather than requiring a separate cash payment for taxes.

Aquestive Therapeutics (AQST) COO sees 72,734 shares withheld for tax

Q: Was Cassie Jung’s Form 4 transaction in AQST an open-market sale of shares?

No, the Form 4 shows a tax-withholding disposition , not an open-market sale. The company withheld 72,734 shares of common stock at $4.18 per share to satisfy her tax liability from vested Performance Stock Units previously granted as compensation.

Q: How many Aquestive Therapeutics (AQST) shares does COO Cassie Jung hold after the reported transaction?

After the tax-withholding disposition, COO Cassie Jung directly owns 202,246 shares of Aquestive Therapeutics common stock. The Form 4 also reports an additional 2,000 shares held indirectly through her spouse, reflecting both direct and indirect ownership positions.

Q: What price was used for the tax-withholding shares in Cassie Jung’s AQST Form 4?

The withheld shares were valued at $4.18 per share for tax purposes. In total, 72,734 shares of Aquestive Therapeutics common stock were delivered back to the issuer to satisfy COO Cassie Jung’s tax withholding obligations from vested Performance Stock Units.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. Chief Operating Officer Cassie Jung reported a compensation-related share disposition tied to tax withholding. On May 5, 2026, 72,734 shares of common stock were withheld by the company at $4.18 per share to cover her tax obligation on vesting Performance Stock Units. After this tax-withholding transaction, she directly holds 202,246 common shares, and there is an additional 2,000-share indirect holding reported in her spouse’s name. The filing does not show an open‑market sale; it reflects routine tax settlement on equity compensation.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jung Cassie

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	72,734	$4.18	$304K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 202,246 shares (Direct, null); Common Stock — 2,000 shares (Indirect, by spouse)

Footnotes (1)

[object Object]

Key Figures

Tax-withheld shares: 72,734 shares Withholding price: $4.18 per share Direct holdings after transaction: 202,246 shares +1 more

4 metrics

Tax-withheld shares 72,734 shares Withheld on May 5, 2026 to satisfy tax obligations on vested PSUs

Withholding price $4.18 per share Value applied to the 72,734 tax-withheld shares

Direct holdings after transaction 202,246 shares Common stock directly owned by Cassie Jung after tax withholding

Indirect holdings via spouse 2,000 shares Common stock reported as held indirectly by spouse

Key Terms

Performance Stock Units, tax withholding obligation, tax-withholding disposition, indirect ownership

4 terms

Performance Stock Units financial

"in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

tax withholding obligation financial

"shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

indirect ownership financial

""direct_or_indirect": "I", "nature_of_ownership": "by spouse""

Form 4 Insider Transactions: What Each Field Means →

05/07/2026 - 05:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jung Cassie

(Last)

(First)

(Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN

NEW JERSEY

07059

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								2,000	I	by spouse
Common Stock	05/05/2026		F		72,734⁽¹⁾	D	$4.18	202,246	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

Was Cassie Jung’s Form 4 transaction in AQST an open-market sale of shares?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. The company withheld 72,734 shares of common stock at $4.18 per share to satisfy her tax liability from vested Performance Stock Units previously granted as compensation.

How many Aquestive Therapeutics (AQST) shares does COO Cassie Jung hold after the reported transaction?

After the tax-withholding disposition, COO Cassie Jung directly owns 202,246 shares of Aquestive Therapeutics common stock. The Form 4 also reports an additional 2,000 shares held indirectly through her spouse, reflecting both direct and indirect ownership positions.

What price was used for the tax-withholding shares in Cassie Jung’s AQST Form 4?

The withheld shares were valued at $4.18 per share for tax purposes. In total, 72,734 shares of Aquestive Therapeutics common stock were delivered back to the issuer to satisfy COO Cassie Jung’s tax withholding obligations from vested Performance Stock Units.